The changing pattern of serum prostate specific antigen in patients with benigh prostatic hyperplasia after combined treatment with finasteride and α-blockers

The 3 year follow-up data

Byung Hyun Soh, Jae Seok Lee, Byungha Chung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Some recent studies have demonstrated that finasteride, a well-known 5 α-reductase inhibitor, can decrease prostate specific antigen (PSA) by approximately 50% during the first 1 year of treatment. We investigated how long-term treatment with finasteride and α-blockers impacts on the serum PSA level of men whose final diagnosis was benign prostatic hyperplasia (BPH). Materials and methods: In a retrospective trial, we evaluated a total of 293 men with lower urinary tract symptoms (LUTS) that were suggestive of BPH. These men were divided into two treatment groups: group A was treated with α-blockers and group C was treated with a combination of finasteride and α-blocker. Comparisons of the two groups were performed by using independent t-tests. The changes in the PSA concentrations from baseline to the time of the final measurements were determined by repeated measures of ANOVA. Results: There was no significant difference in the baseline PSA between the two groups. A statistically significant reduction in the PSA levels was observed at 2 years in C group (p < 0.05), whereas any significant increase were not observed in group A (p > 0.05). In group A, the repeatedly measured PSA levels were 2.67, 2.40, 2.41 and 2.42, respectively. In C group, these were 3.22, 2.09, 1.81 and 1.71 respectively. Conclusions: Our data showed that there was no clinically significant effect of long term treatment with α-blocker on the PSA levels. However, finasteride had significant effect on the serum PSA level during first two years of treatment.

Original languageEnglish
Pages (from-to)372-376
Number of pages5
JournalKorean Journal of Urology
Volume47
Issue number4
DOIs
Publication statusPublished - 2006 Jan 1

Fingerprint

Finasteride
Prostatic Hyperplasia
Prostate-Specific Antigen
Serum
Therapeutics
Lower Urinary Tract Symptoms
Analysis of Variance
Oxidoreductases

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{412d95deb2a048ca887e5c55d5e8b59d,
title = "The changing pattern of serum prostate specific antigen in patients with benigh prostatic hyperplasia after combined treatment with finasteride and α-blockers: The 3 year follow-up data",
abstract = "Purpose: Some recent studies have demonstrated that finasteride, a well-known 5 α-reductase inhibitor, can decrease prostate specific antigen (PSA) by approximately 50{\%} during the first 1 year of treatment. We investigated how long-term treatment with finasteride and α-blockers impacts on the serum PSA level of men whose final diagnosis was benign prostatic hyperplasia (BPH). Materials and methods: In a retrospective trial, we evaluated a total of 293 men with lower urinary tract symptoms (LUTS) that were suggestive of BPH. These men were divided into two treatment groups: group A was treated with α-blockers and group C was treated with a combination of finasteride and α-blocker. Comparisons of the two groups were performed by using independent t-tests. The changes in the PSA concentrations from baseline to the time of the final measurements were determined by repeated measures of ANOVA. Results: There was no significant difference in the baseline PSA between the two groups. A statistically significant reduction in the PSA levels was observed at 2 years in C group (p < 0.05), whereas any significant increase were not observed in group A (p > 0.05). In group A, the repeatedly measured PSA levels were 2.67, 2.40, 2.41 and 2.42, respectively. In C group, these were 3.22, 2.09, 1.81 and 1.71 respectively. Conclusions: Our data showed that there was no clinically significant effect of long term treatment with α-blocker on the PSA levels. However, finasteride had significant effect on the serum PSA level during first two years of treatment.",
author = "Soh, {Byung Hyun} and Lee, {Jae Seok} and Byungha Chung",
year = "2006",
month = "1",
day = "1",
doi = "10.4111/kju.2006.47.4.372",
language = "English",
volume = "47",
pages = "372--376",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "4",

}

TY - JOUR

T1 - The changing pattern of serum prostate specific antigen in patients with benigh prostatic hyperplasia after combined treatment with finasteride and α-blockers

T2 - The 3 year follow-up data

AU - Soh, Byung Hyun

AU - Lee, Jae Seok

AU - Chung, Byungha

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Purpose: Some recent studies have demonstrated that finasteride, a well-known 5 α-reductase inhibitor, can decrease prostate specific antigen (PSA) by approximately 50% during the first 1 year of treatment. We investigated how long-term treatment with finasteride and α-blockers impacts on the serum PSA level of men whose final diagnosis was benign prostatic hyperplasia (BPH). Materials and methods: In a retrospective trial, we evaluated a total of 293 men with lower urinary tract symptoms (LUTS) that were suggestive of BPH. These men were divided into two treatment groups: group A was treated with α-blockers and group C was treated with a combination of finasteride and α-blocker. Comparisons of the two groups were performed by using independent t-tests. The changes in the PSA concentrations from baseline to the time of the final measurements were determined by repeated measures of ANOVA. Results: There was no significant difference in the baseline PSA between the two groups. A statistically significant reduction in the PSA levels was observed at 2 years in C group (p < 0.05), whereas any significant increase were not observed in group A (p > 0.05). In group A, the repeatedly measured PSA levels were 2.67, 2.40, 2.41 and 2.42, respectively. In C group, these were 3.22, 2.09, 1.81 and 1.71 respectively. Conclusions: Our data showed that there was no clinically significant effect of long term treatment with α-blocker on the PSA levels. However, finasteride had significant effect on the serum PSA level during first two years of treatment.

AB - Purpose: Some recent studies have demonstrated that finasteride, a well-known 5 α-reductase inhibitor, can decrease prostate specific antigen (PSA) by approximately 50% during the first 1 year of treatment. We investigated how long-term treatment with finasteride and α-blockers impacts on the serum PSA level of men whose final diagnosis was benign prostatic hyperplasia (BPH). Materials and methods: In a retrospective trial, we evaluated a total of 293 men with lower urinary tract symptoms (LUTS) that were suggestive of BPH. These men were divided into two treatment groups: group A was treated with α-blockers and group C was treated with a combination of finasteride and α-blocker. Comparisons of the two groups were performed by using independent t-tests. The changes in the PSA concentrations from baseline to the time of the final measurements were determined by repeated measures of ANOVA. Results: There was no significant difference in the baseline PSA between the two groups. A statistically significant reduction in the PSA levels was observed at 2 years in C group (p < 0.05), whereas any significant increase were not observed in group A (p > 0.05). In group A, the repeatedly measured PSA levels were 2.67, 2.40, 2.41 and 2.42, respectively. In C group, these were 3.22, 2.09, 1.81 and 1.71 respectively. Conclusions: Our data showed that there was no clinically significant effect of long term treatment with α-blocker on the PSA levels. However, finasteride had significant effect on the serum PSA level during first two years of treatment.

UR - http://www.scopus.com/inward/record.url?scp=33745633340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745633340&partnerID=8YFLogxK

U2 - 10.4111/kju.2006.47.4.372

DO - 10.4111/kju.2006.47.4.372

M3 - Article

VL - 47

SP - 372

EP - 376

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 4

ER -